The effects of HCV infection and management on health-related quality of life.
about
The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virusExtrahepatic manifestations of chronic hepatitis C virus infectionImpact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional OutcomesResidues in a Highly Conserved Claudin-1 Motif Are Required for Hepatitis C Virus Entry and Mediate the Formation of Cell-Cell ContactsEnhanced anti-HCV activity of interferon alpha 17 subtypeAssociation of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon TreatmentPatient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.Occult hepatitis C: how convincing are the current data?Patient's preferences for health scenarios associated with hepatitis C and its treatmentAssessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQInsurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in childrenInterferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients.The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukCost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Major depression during interferon-alpha treatment: vulnerability and prevention.Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus.Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in EgyptReal response to therapy in chronic hepatitis C virus patients: a study from iran.Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN).Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populationsValidation of the chronic liver disease questionnaire in Serbian patients.Innate immunity and alcoholic liver fibrosis.Altered quality of life in the early stages of chronic hepatitis C is due to the virus itselfHepatitis C comorbidities affecting the course and response to therapyEvaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment.Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.Quality of life in cirrhosis.Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument.Extrahepatic manifestations in chronic hepatitis C virus carriers.Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C.Strain-dependent viral dynamics and virus-cell interactions in a novel in vitro system supporting the life cycle of blood-borne hepatitis C virus.A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).The burden of HCV treatment in patients with inherited bleeding disorders.
P2860
Q24652906-46014434-8598-4045-A56F-8F40B96E30E6Q26767084-6D460680-FAEA-4944-BBFA-F63F6A0B2A84Q27487975-E4CA5DE5-830C-4767-A057-31958A306F16Q27488396-1EF72042-332C-4E89-88AB-9796BE8257B6Q27488764-7E9D03F5-8B61-4C2F-A8C4-DB34B9677DBAQ28387292-52C1435B-A587-41CB-863D-AA9A40135306Q30393824-1B620267-64D0-4B5F-B264-9BBDF430465BQ33395436-DC3EEB8C-01F6-4DFC-B266-50476AFB7595Q33573128-A7A05DBE-ED64-4557-AF65-82A6AA946B68Q33813860-4BCAFDAD-B5ED-4334-8E90-223B46E1EFEAQ33819963-1CFDEB25-9F87-420E-8570-961C46122D26Q33938574-9CEEC2A8-2DE9-44F2-9525-EF3B39B0D0A3Q34861058-314FAAFB-D48F-459B-BCFE-F1EBF202D11EQ34876460-B3CF5300-5405-4335-A031-190EA004B8A7Q35066671-8368B7BD-F02D-4111-ADE0-C68D419DF396Q35205389-2D9D815D-A524-4B51-89A6-CE2774D6778DQ35237145-FD7FEFD3-9DB2-4785-A6C2-5787F45750D2Q36063808-BE89CAFA-547D-44A3-BD50-BD82F39BC2E1Q36110868-F43E016B-396A-4B26-860F-F19D6EE9C990Q36256411-EFEFF802-0475-4F99-B0E0-CA8D0662AB32Q36329140-5A4AA74B-8AFA-4D31-AECE-AE9AD92B78AEQ36373495-C27ED96B-8700-4817-9C6D-D528B58C2D93Q36418455-C1C13650-AFD9-4058-A1FE-601EDCCF4F99Q36685609-172F4F9F-EBE0-4733-BCBD-55571826AAD4Q36843554-5972F4C4-A980-4B01-9EAE-5B55B90AC008Q37087516-3AE53732-8114-4439-8B40-10896382C54FQ37108845-20376E28-6B54-42EF-A87F-3A1B81B81DAAQ37333822-1BBB42E1-9699-43ED-AE0B-F97F8B33A27BQ37402438-13FD0B67-5EC8-4984-8BE4-31C907D6E580Q37406590-F5B3273D-9DF4-4027-B22B-032E996927F2Q37975253-44E89891-36E3-4930-B542-CD3635D74D20Q38068356-D719E541-1774-476D-BD21-44704966C16AQ38134312-3B7EAC79-A3BD-46CA-B971-0FD04ECAE69AQ38388423-202A664D-D15D-4201-BFA5-C6A8F53029C8Q38876302-5CD8EE86-744C-4123-8C71-F474B99F19D8Q39394760-D8CA890C-8237-4AEE-B83D-4ECEA3F00E39Q39844023-0ED0DE56-4191-443F-907D-B233AF4722E9Q40134402-EAA106EE-6A7A-4CFC-AAFC-3691EA38CBDEQ40269112-177D0161-261F-41B0-9984-2107FF79998BQ40321131-510D910D-1DF6-45D7-B448-354CBF87D986
P2860
The effects of HCV infection and management on health-related quality of life.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The effects of HCV infection and management on health-related quality of life.
@en
type
label
The effects of HCV infection and management on health-related quality of life.
@en
prefLabel
The effects of HCV infection and management on health-related quality of life.
@en
P2093
P2860
P356
P1433
P1476
The effects of HCV infection and management on health-related quality of life.
@en
P2093
Jillian Kallman
John Kincaid
Zobair Younossi
P2860
P304
P356
10.1002/HEP.21565
P407
P577
2007-03-01T00:00:00Z